Casgevy, Red blood cell and NHS England

Sickle cell gene therapy Casgevy finally cleared for NHS use
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme and with a confidential discount.
NHS England to offer Casgevy for sickle cell disease patients
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) gene therapy to treat a severe form of sickle cell disease (SCD).
Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England
Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
NHS to offer 'groundbreaking' sickle cell therapy as patients given 'very real prospect of cure'
A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use on the NHS in England. The one-time treatment, called Casgevy (exa-cel), has shown remarkable success in clinical trials,
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy,
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.
Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
A £1.65m hope for blood disorder patients is now on offer in Manchester
A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...